The promising results obtained in the two DM models described above encouraged us to assess the therapeutic potential of MB22 in two different cells derived from patients with DM1 that expressed DMPK transcripts with very long CUGexp (DM1-1 and DM1-2). The gene discussed is DMPK; the disease is myotonic dystrophy type 1.